



Investor Package

Moving pharmacy forward.

50

Technology **Fast 50**
2024 CANADA
COMPANIES-TO-WATCH WINNER
Deloitte.

Cautionary Note Regarding Forward-Looking Statements

Information in this press release that involves Avricore Health's expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy

1300

Estimates heart attack/strokes prevented via blood pressure checks in UK pharmacies

£11,000,000,000

Estimated annual savings potential for dedication and management of chronic illness in pharmacy

Conv. Jan 2025: AUD \$21.6 billion CAD \$19.4 billion. EUR €13 billion USD \$13.6 billion

<https://pharmaceutical-journal.com/article/news/pharmacist-led-cardiovascular-disease-interventions-provide-highest-return-on-investment-says-nhs-report>



HealthTab Solution

Better. Now.

Avricore Health Inc. (TSXV: AVCR) is focused on moving the pharmacy forward into the future. Through its flagship offering HealthTab™ (a wholly owned subsidiary), its mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.

HealthTab Solution

Turnkey POCT for pharmacy.



HealthTab™ brings the best point-of-care analyzers onto a single, secure cloud-based network. It gives patients and pharmacists access to actionable data in real time, when it matters most.

TSXV: AVCR



The Problem

Healthcare needs new tools.

Healthcare systems around the world are feeling the strain of a reactive model that is costly and ineffective. At Avricore Health, we believe in a more accessible and proactive approach that empowers patients and improves outcomes.

The Problem

Chronic disease epidemic.

Chronic illness causes [71% of deaths worldwide](#) and is responsible for the majority of the global burden of disease. Yet these conditions are preventable and can be managed proactively with medication and lifestyle modification.

\$68B

Direct healthcare costs in Canada from chronic illness

70%

Of social and health spending in the UK goes towards chronic illness


1/3

Canadians currently has diabetes or prediabetes

Pharmacy Shift

Pharmacy is transforming.

Pharmacies are investing in technology to facilitate the [future of their practice](#) as it shifts from pill dispensary to health consultancy. As trusted health experts, pharmacists can then provide high value clinical services, such as early disease risk identification and prevention.



“

I'm so excited to have HealthTab in my store because I believe it demonstrates a new and better way to do pharmacy practice.


– **Mohamed Adel Elsabakhawi**


Pharmacist & Associate Owner,
Shoppers Drug Mart

Market Potential

Growth of POCT.

The point-of-care testing market is poised for [significant growth](#) over the next eight years to meet the increasing demand for fast, accurate health data in the community.





Actionable
Data

Digital Health Trend

Empowered patients.

The digital health revolution is finally putting patients at the centre of their own care. With better access to actionable data, they can take an active role in achieving their health goals.

‘HealthTab is focused on becoming the world’s largest, most reliable POCT network in community pharmacies.’

– **Hector Bremner**

CEO, Avricore
Health

Competitive Advantage

The HealthTab difference.



1st to Market

Dedicated poct system for pharmacy



Easily Integrated

API allows for seamless data integration



Quality Control

World-class QC programs provided by CEQAL



Pharmacy Focused

Expert knowledge of industry and operations



Harmonized Data

Single testing network for consistent results




Patient Centered

Designed for convenience and quality of care

HealthTab

23 biomarkers in minutes.

HealthTab™ provides fast, lab-accurate results for screening and monitoring chronic disease as well as testing for some common viral and bacterial infections. Data can be viewed immediately online.



Instruments

Testing menu.

Through agreements with Abbott Rapid Diagnostics, HealthTab™ currently supports the following POCT devices.



AFINION 2

Tests:

A1c, Lipid Profile,
C-Reactive Protein



ID NOW

Tests:

RSV, Strep, Influenza A & B

Instruments

New insights.

The world's most accurate and popular blood glucose meter for people living with diabetes has been successfully integrated into HealthTab™. This is the first time near-to-patient data has been reported into patient's accounts, providing time-in-range data to greatly enhance the pharmacists' ability to support meaningful consultations and advice.

**Contour®
next GEN**)
Blood Glucose
Monitoring System



‘We’re proud to be a part of this amazing journey with HealthTab as we believe POCT in pharmacies is the future.’

– **Daniel Saint-Pierre**

GM, Abbott Rapid Diagnostics

HealthTab

Revenue model.

Pharmacies

100,000+

- Addressable market of community pharmacies in Canada, US & UK.

System Fee

\$250/mth

- Monthly cost to lease the system per location (based on a single instrument).

Test Margin


30%

- HealthTab also generates revenue with each test (consumable reagents).

Proven

HealthTab works.

HealthTab™ has been used successfully to test tens of thousands of patients across Canadian pharmacies. Our platform's rapid, cost-effective scalability has been demonstrated domestically and are we now taking it international. Most importantly, we've identified thousands of previously undiagnosed conditions, enabling pharmacists to provide vital care to underserved patients. These results confirm our vision: community pharmacists, equipped with HealthTab™, helping people live better.



TSXV: AVCR

New Markets

Going International.



HealthTab™ has been selected by a collaborative involving the internationally renowned Barts Heart Centre and HEART UK to assess the feasibility of community pharmacists in the UK's ability to complement opportunistic blood pressure checks with cholesterol testing to assess overall cardiovascular risk and build on the clinical services offered.

The feasibility study seeks deeper insights and ways to build off the successful delivery of over 930,000 blood pressure checks in just over a year through approximately 6000 pharmacies as part of the NHS' initiative to support risk identification and prevention of cardiovascular disease. In October of 2024, the NHS Confederation's report on NHS care investments found that the highest return came from pharmacy and managing chronic disease.

TSXV: AVCR

2024 Accomplishments.

4 consecutive years of record revenue growth

Achieved net profitability

Added significant new features in anticipation of UK market expansion

Received 2024 Deloitte Fast 50 *Ones to Watch* Award for growth

Priorities 2025.

01

New Growth

Building with Canadian
Customers

02

New Markets

Achieve feasibility objectives
in. UK for successful
expansion

03

New Features

Deploy new AI features
which drive better health
insights

04

New Partners

Deepen interoperability
partnerships to expand
reach

2023 Venture 50.

In 2023, AVCR was one of the most traded companies for that year in the Life Science category, demonstrating strong market support and growth.

Avricore Health Inc.



We made the list!

TSXV:**AVCR**

tsx.com/venture50
#V50





Technology Fast 50 ranking


Clean Technology ranking

Enterprise—Industry Leaders ranking

Companies-to-Watch ranking

2024 Companies-to-Watch ranking

1	Inmotive – North York ON	8829%
2	BrainBox AI – Montreal QC	4649%
3	CapIntel – Toronto ON	4048%
4	Qube Technologies – Calgary AB	3836%
5	PostGrid – Toronto ON	3687%
6	veritree – Vancouver BC	3257%
7	Float – Toronto ON	3126%
8	Avricore Health (TSX-V: AVCR) – Vancouver BC	2738%
9	Novisto – Montreal QC	1791%
10	Tailscale – Toronto ON	1283%
11	InnerSpace – Newmarket ON	1115%
12	TryCycle Data Systems – Ottawa ON	757%
13	Vetster – Toronto ON	562%
14	Kahi – Ottawa ON	542%
15	MinuteBox – Thornhill ON	540%



Cap Table.

AVCR strategically funds its operations and growth through revenue generation, minimizing reliance on capital raises.

The company prioritizes creating strong revenue streams and enhancing market valuation.

ISSUED AND OUTSTANDING

SHARES

POSSIBLE PROCEEDS

101,289,664

EXPIRY DATE

PRICE

OPTIONS

\$ CAD

November 18, 2025	\$0.08	500,000	40,000
December 8, 2025	\$0.08	710,000	56,800
January 28, 2026	\$0.19	150,000	28,500
March 22, 2026	\$0.25	1,800,000	450,000
August 10, 2027	\$0.15	2,675,000	401,250
August 11, 2027	\$0.15	100,000	15,000
October 12, 2027	\$0.16	300,000	48,000
May 15, 2028	\$0.28	1,825,000	511,000
June 21, 2028	\$0.20	400,000	80,000
September 15, 2028	\$0.20	140,000	28,000
July 1, 2029	\$0.18	300,000	54,000
August 30, 2029	\$0.29	3,361,000	974,690
		12,261,000	2,687,240

FULLY DILUTED

113,550,664

2,687,240



Avricore Health Inc.
1120-789 West Pender St.
Vancouver, BC, V6C 1H2

Contact
[info@avricore
health.com](mailto:info@avricorehealth.com)

Thank You
